|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1989-03-31 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1988-08-18 |
Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of 40mgm/ml 35 ml Suspension and Pfizer (Diflucan®) 40 mg/ml 35 ml Fluconazole Suspension of Participants Under Fed Condition
The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Flucanazole 40mgm/ml 35 ml Suspension and Pfizer (Diflucan®) 40 mg/ml 35 ml Fluconazole Suspension Under Fed Condition
Orfadin and Nitinosine Study
he purpose of this study is to determine whether Nitisinone 10 mg Tablets (Test Product are bioequivalent to the reference product Orfadin 10 mg
A Bio Equivalence Study of DOXIL and Doxorubicin in Subjects With Lymphoma, Leukemia and Carcinoma
Doxil or Doxorubicin to be administered was administered in a dose of 50 mg/m2 as infusion over 15 minutes. Blood samples to be obtained at 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours
100 项与 Sutphin Drugs Inc 相关的临床结果
0 项与 Sutphin Drugs Inc 相关的专利(医药)
100 项与 Sutphin Drugs Inc 相关的药物交易
100 项与 Sutphin Drugs Inc 相关的转化医学